ATE43635T1 - Verfahren zur herstellung von interferon und expressionsvektoren dafuer. - Google Patents

Verfahren zur herstellung von interferon und expressionsvektoren dafuer.

Info

Publication number
ATE43635T1
ATE43635T1 AT83106730T AT83106730T ATE43635T1 AT E43635 T1 ATE43635 T1 AT E43635T1 AT 83106730 T AT83106730 T AT 83106730T AT 83106730 T AT83106730 T AT 83106730T AT E43635 T1 ATE43635 T1 AT E43635T1
Authority
AT
Austria
Prior art keywords
interferon
preparation
expression vectors
bacteriophage lambda
derived
Prior art date
Application number
AT83106730T
Other languages
German (de)
English (en)
Inventor
Robert M Crowl
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE43635T1 publication Critical patent/ATE43635T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C12N15/73—Expression systems using phage (lambda) regulatory sequences
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/811—Interferon
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/848—Escherichia
    • Y10S435/849—Escherichia coli
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/142—Interferon

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT83106730T 1982-07-12 1983-07-08 Verfahren zur herstellung von interferon und expressionsvektoren dafuer. ATE43635T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/397,388 US4582800A (en) 1982-07-12 1982-07-12 Novel vectors and method for controlling interferon expression
EP83106730A EP0099084B1 (de) 1982-07-12 1983-07-08 Verfahren zur Herstellung von Interferon und Expressionsvektoren dafür

Publications (1)

Publication Number Publication Date
ATE43635T1 true ATE43635T1 (de) 1989-06-15

Family

ID=23570982

Family Applications (1)

Application Number Title Priority Date Filing Date
AT83106730T ATE43635T1 (de) 1982-07-12 1983-07-08 Verfahren zur herstellung von interferon und expressionsvektoren dafuer.

Country Status (6)

Country Link
US (1) US4582800A (enExample)
EP (1) EP0099084B1 (enExample)
JP (2) JPS5928479A (enExample)
KR (1) KR900005776B1 (enExample)
AT (1) ATE43635T1 (enExample)
DE (1) DE3379959D1 (enExample)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA831094B (en) * 1982-02-22 1983-11-30 Biogen Nv Dna sequences,recombinant dna molecules and processes for producing human immune interferon-like polypeptides
IL68100A0 (en) * 1982-03-24 1983-06-15 Takeda Chemical Industries Ltd Novel dna and use thereof
JPH0787797B2 (ja) * 1982-05-20 1995-09-27 サントリー株式会社 ヒト・ガンマ・インタ−フエロン様ポリペプチドの製造法
CA1303530C (en) * 1983-01-21 1992-06-16 Michael Courtney EXPRESSION VECTORS AND THEIR USE FOR THE PREPARATION OF A PROTEIN HAVING HUMAN .alpha. -ANTITRYPSIN ACTIVITY
WO1984003300A1 (fr) * 1983-02-24 1984-08-30 Inst Organicheskogo Sinteza Ak Interferon n humain leucocytaire et son procede d'obtention dans des cellules bacteriennes
JPH0740925B2 (ja) * 1983-03-14 1995-05-10 協和醗酵工業株式会社 新規ヒトインタ−フエロン−γポリペプチド
FR2556365B1 (fr) * 1983-12-09 1987-07-31 Transgene Sa Vecteurs de clonage et d'expression de l'interferon-g, bacteries transformees et procede de preparation de l'interferon-g
JPS60172999A (ja) * 1983-12-20 1985-09-06 Suntory Ltd 新規な塩基性ポリペプチドおよびその製造法
US4935370A (en) * 1983-12-23 1990-06-19 Pfizer Inc. Expression plasmids for improved production of heterologous protein in bacteria
DE3484926D1 (de) * 1983-12-23 1991-09-19 Pfizer Expressionsplasmide fuer die herstellung eines heterologen proteins in bakterien.
US4711845A (en) * 1984-08-31 1987-12-08 Cetus Corporation Portable temperature-sensitive control cassette
US5248666A (en) * 1984-03-23 1993-09-28 Oncogen Methods for inhibiting neoplastic cell proliferation using platelet factor 4
WO1985005618A1 (fr) * 1984-06-06 1985-12-19 Takeda Chemical Industries, Ltd. Procede de preparation de derives de l'interferon
BE901119A (fr) * 1984-11-23 1985-03-15 Wallone Region Procede de preparation de plasmides vecteurs capables de transformer un hote bacterien escherichia coli et d'y promouvoir et controler l'expression d'un adn heterologue.
US4772555A (en) * 1985-03-27 1988-09-20 Genentech, Inc. Dedicated ribosomes and their use
US5618715A (en) * 1985-12-20 1997-04-08 Oncogen Limited Partnership Oncostatin M and novel compositions having anti-neoplastic activity
GB8701848D0 (en) * 1987-01-28 1987-03-04 Celltech Ltd Polypeptides
SU1703692A1 (ru) * 1987-02-09 1992-01-07 Всесоюзный научно-исследовательский институт генетики и селекции промышленных микроорганизмов Рекомбинантна плазмидна ДНК @ -1 @ 1-13, кодирующа синтез фибробластного интерферона ( @ I) человека, способ ее конструировани , штамм бактерий ЕSснеRIснIа coLI - продуцент @ I-интерферона человека
JPH01503513A (ja) * 1987-03-02 1989-11-30 オンコゲン 血小板関連増殖調節剤
US5250415A (en) * 1987-04-08 1993-10-05 Merck Patent Gesellschaft Mit Beschrankter Haftung Process for the preparation of glucose dehydrogenase from Bacillus megaterium
DE3711881A1 (de) * 1987-04-08 1988-10-27 Merck Patent Gmbh Verfahren zur herstellung von glucosedehydrogenase aus bacillus megaterium
JPS6463395A (en) 1987-05-04 1989-03-09 Oncogen Oncostatin m and novel composition having antitumor activity
ES2081801T3 (es) * 1987-10-30 1996-03-16 Bristol Myers Squibb Co Plasmidos de expresion.
CA1335357C (en) * 1987-10-30 1995-04-25 Timothy M. Rose Expression systems for preparation of polypeptides in prokaryotic cells
EP0372005A4 (en) * 1987-10-30 1990-06-26 Oncogen EXPRESSION SYSTEMS FOR THE PREPARATION OF POLYPEPTIDES IN PROKARYOTIC CELLS.
US5268284A (en) * 1988-03-11 1993-12-07 The Upjohn Company Ribosome binding site
GR1002113B (en) * 1988-09-02 1996-02-02 Oncogen Expression systems for preparation of polypeptides in prokaryotic cells
US5726039A (en) * 1994-07-21 1998-03-10 Yissum Research Development Co. Of The Hebrew University Of Jerusalem Vectors and transformed host cells for recombinant protein production at reduced temperatures
WO1996017951A2 (en) * 1994-12-09 1996-06-13 Rpms Technology Limited Identification of genes responsible for in vivo survival of microorganisms
GB9712370D0 (en) 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems
BR9914479A (pt) * 1998-09-04 2001-06-26 Creatogen Ag Mutantes sp12 de salmonella atenuada como carreadores antìgenos
GB9910812D0 (en) * 1999-05-10 1999-07-07 Microscience Ltd Vaccine composition
GB0008419D0 (en) * 2000-04-05 2000-05-24 Bioinvent Int Ab A method for invitro molecular evolution of antibody function
GB0008966D0 (en) 2000-04-13 2000-05-31 Imp College Innovations Ltd Vectors for gene therapy
GB0217033D0 (en) 2002-07-23 2002-08-28 Delta Biotechnology Ltd Gene and polypeptide sequences
GB0226105D0 (en) * 2002-11-08 2002-12-18 St Georges S Entpr Ltd Pain relief agents
GB0304993D0 (en) * 2003-03-05 2003-04-09 Univ Nottingham Trent Novel screening method
AU2005203962C1 (en) * 2004-01-05 2012-11-08 Antisoma Research Limited Interleukin-12 targeted to oncofoetal fibronectin
GB0420091D0 (en) * 2004-09-10 2004-10-13 Univ Nottingham Trent Medical implant materials
US20060193849A1 (en) * 2005-02-25 2006-08-31 Antisoma Plc Biological materials and uses thereof
GB0514661D0 (en) * 2005-07-16 2005-08-24 Medical Res Council Methods
PT1760089E (pt) 2005-09-05 2009-10-19 Immatics Biotechnologies Gmbh Peptídeos associados a tumores que se ligam a moléculas de classe i ou ii do antigénio leucocitário humano (hla) e correspondente vacina anti-cancerígena
DK1806359T3 (da) 2005-09-05 2010-06-14 Immatics Biotechnologies Gmbh Tumorassocierede peptider, der bindes promiskuøst til Humant Leukocyt-Antigen (HLA) klasse II molekyler
GB0519398D0 (en) * 2005-09-23 2005-11-02 Antisoma Plc Biological materials and uses thereof
GB0607354D0 (en) * 2006-04-12 2006-05-24 Bioinvent Int Ab Agent, Composition And Method
GB0607798D0 (en) * 2006-04-20 2006-05-31 Alligator Bioscience Ab Novel polypeptides and use thereof
CN101657720A (zh) * 2006-05-31 2010-02-24 荷兰联合利华有限公司 筛选改变皮肤和/或头发色素沉着的化合物的方法
DK2183361T3 (en) 2007-07-27 2015-07-27 Immatics Biotechnologies Gmbh Novel immunotherapy against brain tumors
KR101351195B1 (ko) 2007-07-27 2014-01-14 이매틱스 바이오테크놀로지스 게엠베하 면역 치료를 위한 새로운 면역원성 에피톱
RU2506275C2 (ru) 2007-11-01 2014-02-10 Астеллас Фарма Инк. Иммуносупрессорные полипептиды и нуклеиновые кислоты
US20100249373A1 (en) * 2007-11-27 2010-09-30 Richard Martin Ogborne Screening methods
DK2105501T3 (da) 2008-03-27 2015-11-23 Immatics Biotechnologies Gmbh Hidtil ukendt immunterapi mod neuronale tumorer og hjernetumorer
PL2119726T5 (pl) 2008-05-14 2018-04-30 Immatics Biotechnologies Gmbh Nowe i silne peptydy MHC klasy II pochodzące z surwiwiny i neurokanu
WO2009158240A1 (en) 2008-06-16 2009-12-30 Emergent Product Development Uk Limited Salmonella vectored vaccines against chlamydia and methods of use
ES2536465T3 (es) 2008-10-01 2015-05-25 Immatics Biotechnologies Gmbh Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres
GB0905790D0 (en) 2009-04-03 2009-05-20 Alligator Bioscience Ab Novel polypeptides and use thereof
ES2635316T3 (es) 2009-12-18 2017-10-03 Kancera Ab Anticuerpos contra ROR1 que pueden inducir muerte celular de LLC
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201019331D0 (en) 2010-03-19 2010-12-29 Immatics Biotechnologies Gmbh Methods for the diagnosis and treatment of cancer based on AVL9
GB201020995D0 (en) 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
GB2490655A (en) 2011-04-28 2012-11-14 Univ Aston Modulators of tissue transglutaminase
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
GB201219678D0 (en) 2012-11-01 2012-12-12 Benf Ab Ketone body inhibitors and uses thereof
EP3587439A3 (en) 2013-03-01 2020-03-11 Boehringer Ingelheim Animal Health USA Inc. Improved quantification of vaccine compositions
TWI777194B (zh) 2013-08-05 2022-09-11 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（一）
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
GB201408255D0 (en) 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
GB201411037D0 (en) 2014-06-20 2014-08-06 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
HRP20211327T1 (hr) 2014-12-23 2022-01-21 Immatics Biotechnologies Gmbh Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova
PT3388075T (pt) 2015-03-27 2023-08-18 Immatics Biotechnologies Gmbh Novos péptidos e combinações de péptidos para uso em imunoterapia contra vários tumores
GB201505585D0 (en) 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
GB201507030D0 (en) 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
GB201507719D0 (en) 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
MA42294B1 (fr) 2015-07-01 2020-11-30 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
CR20170579A (es) 2015-07-06 2018-05-25 Immatics Biotechnologies Gmbh Nuevos péptidos y combinación de péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres.
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
GB201522667D0 (en) 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201602918D0 (en) 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
CN116375797A (zh) 2016-03-01 2023-07-04 伊玛提克斯生物技术有限公司 用于膀胱癌和其他癌症免疫治疗的肽、肽组合物和细胞类药物
GB201603987D0 (en) 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
PL3430037T3 (pl) 2016-03-16 2022-12-19 Immatics Biotechnologies Gmbh Transfekowane komórki t oraz receptory komórek t do stosowania w immunoterapii przeciwnowotworowej
CR20220248A (es) 2016-03-16 2022-07-18 Immatics Biotechnologies Gmbh Células t transfectadas y receptores de células t de utilidad en inmunoterapias contra el cáncer
SG10202110335PA (en) 2016-04-06 2021-10-28 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers
TW202304970A (zh) 2016-08-26 2023-02-01 德商英麥提克生物技術股份有限公司 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
MA47367B1 (fr) 2017-01-27 2023-06-28 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
SG10202107869QA (en) 2017-04-10 2021-08-30 Immatics Biotechnologies Gmbh Peptides and combination thereof for use in the immunotherapy against cancers
US10899819B2 (en) 2017-04-10 2021-01-26 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers
US11427614B2 (en) 2017-04-10 2022-08-30 Immatics Biotechnologies Gmbh Peptides and combination thereof for use in the immunotherapy against cancers
JP2020530759A (ja) 2017-07-07 2020-10-29 イマティクス バイオテクノロジーズ ゲーエムベーハー Ｎｓｃｌｃ、ｓｃｌｃ、およびその他のがんをはじめとする肺がんに対する免疫療法で使用するための新規ペプチドおよびペプチド併用
WO2019007974A1 (en) 2017-07-07 2019-01-10 Immatics Biotechnologies Gmbh NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF LUNG CANCER, INCLUDING NSCLC, CPPC AND OTHER CANCERS
DE102018107224A1 (de) 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
TW202016131A (zh) 2018-05-16 2020-05-01 德商英麥提克生物技術股份有限公司 用於抗癌免疫治療的肽
US10925947B2 (en) 2018-06-29 2021-02-23 Immatics Biotechnologies Gmbh A*03 restricted peptides for use in immunotherapy against cancers and related methods
TW202019955A (zh) 2018-07-31 2020-06-01 德商英麥提克生物技術股份有限公司 B*07 限制肽和肽組合的抗癌免疫治療和相關方法
TW202028224A (zh) 2018-09-17 2020-08-01 德商英麥提克生物技術股份有限公司 B*44限制肽在抗癌免疫治療的用途和相關方法
TW202024121A (zh) 2018-09-18 2020-07-01 德商英麥提克生物技術股份有限公司 A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法
TW202039535A (zh) 2018-12-18 2020-11-01 德商英麥提克生物技術股份有限公司 B*08限制肽和肽組合物抗癌免疫治療和相關方法
DE102020125457A1 (de) 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
TW202229312A (zh) 2020-09-29 2022-08-01 德商英麥提克生物技術股份有限公司 由非ｈｌａ－ａ*０２顯露以用於不同類型癌症之免疫治療的醯胺化肽及其脫醯胺化對應物
TW202241925A (zh) 2021-01-15 2022-11-01 德商英麥提克生物技術股份有限公司 用於不同類型癌症免疫治療的ｈｌａ展示肽
WO2025040598A2 (en) 2023-08-18 2025-02-27 Immatics Biotechnologies Gmbh Peptides displayed by mhc for use in immunotherapy against different types of cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8000127A (nl) * 1979-01-15 1980-07-17 Harvard College Werkwijze voor het vormen van prokaryotische of eukaryotische proteinen alsmede een daarbij toepasbaar gekoppeld gen.
IT1144705B (it) * 1980-03-17 1986-10-29 Harvard College Produzione ottimale di polipeptidi con impiego di geni fusionati
AU564690B2 (en) * 1980-04-03 1987-08-20 Biogen Idec Ma Inc. Process for producing human fibroblast interferon-like polypeptides using recombinant dna
NO811119L (no) * 1980-06-06 1981-12-07 Biogen Nv Forbedrede baerere, samt fremgangsmaate ved fremstilling av disse og for aa uttrykke klonede gener
ZA814375B (en) * 1980-07-01 1982-07-28 Hoffmann La Roche Interferons and process for their preparation
DK489481A (da) * 1980-11-10 1982-05-11 Searle & Co Plasmidvektor og frmgangsmaade til fremstilling deraf
IL68100A0 (en) * 1982-03-24 1983-06-15 Takeda Chemical Industries Ltd Novel dna and use thereof

Also Published As

Publication number Publication date
KR900005776B1 (ko) 1990-08-11
US4582800A (en) 1986-04-15
EP0099084B1 (de) 1989-05-31
JPS60149397A (ja) 1985-08-06
JPH0141312B2 (enExample) 1989-09-05
DE3379959D1 (en) 1989-07-06
JPS5928479A (ja) 1984-02-15
JPH0248235B2 (enExample) 1990-10-24
EP0099084A3 (en) 1985-01-09
KR840005490A (ko) 1984-11-14
EP0099084A2 (de) 1984-01-25

Similar Documents

Publication Publication Date Title
ATE43635T1 (de) Verfahren zur herstellung von interferon und expressionsvektoren dafuer.
ATE61228T1 (de) Immunogener protein- oder peptidkomplex, verfahren zur herstellung dieses komplexes und seine verwendung als immunstimulans und als impfstoff.
ZA951008B (en) N-terminally chemically modificed protein compositions and method
PT76546B (en) Process for preparing functional human urokinase protein
EP0219106A3 (en) Polypeptides that elicit antibodies against aids virus
IL59880A (en) Human le form interferon proteins,method of producing same and formulations comprising them
HU9200548D0 (en) Improved activity process of recombined proteins
DE3683267D1 (de) Gm-csf-protein, seine derivate, herstellung solcher proteine und ihre verwendung.
DE68918673D1 (de) IgG-bindendes Protein H, kodierendes Gen dafür und Verfahren zu seiner Herstellung.
HK15184A (en) Fluor-containing 1,4-dihydrophyridines,pharmaceuticals containing them and process for their preparation
DE3061854D1 (en) Process for the preparation of interferon and culture medium composition used in it
DE59101580D1 (de) Trägergebundene rekombinante proteine, verfahren zur herstellung und verwendung als immunogene und vakzine.
ES8503238A1 (es) Procedimiento de preparar concentrados y nutrimentos proteinicos
ATE82985T1 (de) Strukturelles phosphoprotein (pp 150) des menschlichen cytomegalovirus, seine herstellung und verwendung.
ATE118982T1 (de) Verfahren zur herstellung von transparenten milchmolkeproteinen und milchmolkeproteinprodukte.
GB2171703B (en) Expression-secretion vector for gene expression and protein secretion, recombinant dna including the vector, and method of producing proteins by use of the re
ATE43139T1 (de) Klonierungs- und expressionsvektoren fuer gammainterferon, transformierte bakterien und verfahren zur herstellung von gamma-interferon.
ATE125298T1 (de) Verfahren zur herstellung von motilinähnlichen polypeptiden und seine expression.
DE3485148D1 (de) Plasmidvektor und seine verwendung.
EP0490383A3 (en) Peptides of the hiv-gag protein, their preparation and use
ATE2144T1 (de) Verfahren zur herstellung von carbazolen und zwischenprodukte dafuer.
JPS54147950A (en) Method for improving quality of soybean or soybean protein product
DE3167246D1 (en) Process for producing stabilized hydrolysates of animal proteins, products obtained and dietetic and therapeutic application
EP0195087A4 (en) Cyclic double-stranded dna, process for its preparation, microorganism containing said cyclic double-stranded dna, and process for preparing protein containing antigen determinant site of poliovirus capside protein vp1 using the same.
DD133231A1 (de) Verfahren zur herstellung von peptiden,proteinen und proteinsequenzen

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee